Lantheus (LNTH) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company history and strategic direction

• Originated in 1956 with a focus on radiopharmaceuticals, evolving into a market leader in the field.

• Recent CEO transition brought a focus on diversification and increased M&A activity to reduce concentration risk.

• Expansion into therapeutic oncology and deeper engagement in dementia and Alzheimer's disease.

Commercial performance and market strategy

• PYLARIFY has become a blockbuster, on track to surpass $1 billion in sales, driven by first-mover advantage and robust distribution.

• Investments in sales channels, market access, and guideline changes accelerated adoption.

• Focus remains on growing the total addressable market and deepening physician education.

Competitive landscape and growth outlook

• Several competitors exist in PSMA PET imaging, but the company is focused on market expansion rather than defending share.

• Growth is expected to continue in 2025 and beyond, though specific guidance was not provided.